Bristol-Myers Squibb said it will acquire IFM Therapeutics in an effort to strengthen its cancer portfolio. BMS will make a $300 million upfront payment, while IFM investors will also benefit from additional contingent payments that could reach $1.01 billion based on the achievement of specific milestones.
Bristol-Myers boosts cancer pipeline with IFM Therapeutics acquisition
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.